MedPath

Medimetriks Pharmaceuticals, Inc.

Medimetriks Pharmaceuticals, Inc. logo
🇹🇹Trinidad and Tobago
Ownership
Subsidiary
Established
2008-01-01
Employees
101
Market Cap
-
Website
http://www.medimetriks.com

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 2:1

Drug Approvals

13

FDA:13

Drug Approvals

Sumaxin

Approval Date
Dec 15, 2023
FDA

Synalar

Approval Date
Dec 8, 2023
FDA

Synalar

Approval Date
Nov 29, 2023
FDA

Clodan

Approval Date
Nov 20, 2023
FDA

Clindacin P

Approval Date
Nov 15, 2023
FDA

Neuac

Approval Date
Nov 15, 2023
FDA

Clindacin ETZ

Approval Date
Nov 14, 2023
FDA

Tovet (emollient formulation)

Approval Date
Oct 27, 2023
FDA

Ketodan

Approval Date
Oct 25, 2023
FDA

Neo-Synalar

Approval Date
Jan 10, 2023
FDA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (100.0%)

Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: MM36 topical ointment, 1%
First Posted Date
2016-10-26
Last Posted Date
2018-11-19
Lead Sponsor
Medimetriks Pharmaceuticals, Inc
Target Recruit Count
32
Registration Number
NCT02945657
Locations
🇵🇦

Medimetriks Investigational Site, Panama City, Panama

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.